Bortezomib will boost the stage or influence of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Enhanced flibanserin adverse outcomes may arise if coadministered with multiple weak CYP3A4 inhibitors. B: Can be suitable. Both animal experiments clearly show no threat but human reports not offered or animal research confirmed https://deanchmsv.blazingblog.com/26823844/detailed-notes-on-dup-747